Myeloid-Derived Suppressor Cells in Colorectal Cancer

Front Immunol. 2020 Aug 7:11:1526. doi: 10.3389/fimmu.2020.01526. eCollection 2020.

Abstract

Colorectal cancer (CRC) remains one of the most common malignancies diagnosed worldwide. The pathogenesis of CRC is complex and involves, among others, accumulation of genetic predispositions and epigenetic factors, dietary habits, alterations in gut microbiota, and lack of physical activity. A growing body of evidence suggests that immune cells play different roles in CRC, comprising both pro- and anti-tumorigenic functions. Immunosuppression observed during cancer development and progression is a result of the orchestration of many cell types, including myeloid-derived suppressor cells (MDSCs). MDSCs, along with other cells, stimulate tumor growth, angiogenesis, and formation of metastases. This article focuses on MDSCs in relation to their role in the initiation and progression of CRC. Possible forms of immunotherapies targeting MDSCs in CRC are also discussed.

Keywords: T regulatory cells (Tregs); arginase-1 (ARG1); colorectal cancer (CRC); inducible NO synthase (iNOS); myeloid-derived suppressor cells (MDSCs).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers
  • Cell Plasticity
  • Colorectal Neoplasms / epidemiology
  • Colorectal Neoplasms / etiology*
  • Colorectal Neoplasms / metabolism*
  • Colorectal Neoplasms / therapy
  • Combined Modality Therapy
  • Disease Management
  • Disease Susceptibility* / immunology
  • Humans
  • Myeloid-Derived Suppressor Cells / immunology*
  • Myeloid-Derived Suppressor Cells / metabolism*
  • Population Surveillance
  • Treatment Outcome

Substances

  • Biomarkers